1.A Case of Transmesocolic Hernia in Elderly Person without a History of Operation.
Hoon Suk PARK ; Jin Il KIM ; Myoung Seok KIM ; Soon Sub KIM ; Se Hyun CHO ; Soo Heon PARK ; Joon Yeol HAN ; Jae Kwang KIM
The Korean Journal of Gastroenterology 2006;48(4):286-289
Internal hernia is defined as the herniation of viscera through an anatomic or pathologic opening within the boundaries of peritoneal cavity. Transmesocolic hernia, a subtype of internal hernia, has a herniated sac through the transverse mesocolon. Transmesocolic hernia has been rarely described in the literature, and most of reported cases were associated with a history of operation or congenital anormaly. A 72-year-old female with chronic intermittent abdominal pain and bloating was admitted. Small bowel series showed multiple jejunal loops confined to the left upper quadrant of abdomen. Abdomen spiral computed tomography (CT) showed a cluster of mildly dilated small bowel loops with mesenteries on the same area. On the three-dimensional reconstruction CT scan, a herniated sac through the transverse mesocolon was identified. She was diagnosed as transmesocolic hernia by using the three-dimensional reconstruction CT and small bowel series, without surgical exploration. The symptoms were managed with conservative measures.
Colitis, Ulcerative/*drug therapy
;
Cyclosporine/*therapeutic use
;
Drug Tolerance
;
Humans
;
Hydrocortisone/administration & dosage/*therapeutic use
;
Injections, Intravenous
;
Methylprednisolone/administration & dosage/*therapeutic use
2.Guidelines for the Management of Ulcerative Colitis.
Chang Hwan CHOI ; Young Ho KIM ; You Sun KIM ; Byong Duk YE ; Kang Moon LEE ; Bo In LEE ; Sung Ae JUNG ; Won Ho KIM ; Heeyoung LEE
The Korean Journal of Gastroenterology 2012;59(2):118-140
Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by a relapsing and remitting course. The quality of life can decreases significantly during exacerbations of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies are currently used for the management of UC. However, many challenging issues exist and sometimes these lead to differences in practice between clinicians. Therefore, Inflammatory Bowel Diseases (IBD) Study Group of Korean Association for the Study of Intestinal Diseases (KASID) set out the Korean guidelines for the management of UC. These guidelines are made by the adaptation using several foreign guidelines and encompass treatment of active colitis, maintenance of remission and indication for surgery in UC. The specific recommendations are presented with the quality of evidence. These are the first Korean treatment guidelines for UC and will be revised with new evidences on treatment of UC.
Administration, Oral
;
Adrenal Cortex Hormones/therapeutic use
;
Anti-Inflammatory Agents/therapeutic use
;
Antibodies, Monoclonal/therapeutic use
;
Antimetabolites, Antineoplastic/therapeutic use
;
Azathioprine/therapeutic use
;
Colitis, Ulcerative/*drug therapy/surgery
;
Humans
;
Hydrocortisone/therapeutic use
;
Injections, Intravenous
;
Mesalamine/therapeutic use
;
Methylprednisolone/therapeutic use
;
Severity of Illness Index
;
Sulfasalazine/therapeutic use
3.A case of insulinoma complicated with secondary adrenal insufficiency.
Journal of Zhejiang University. Medical sciences 2017;46(6):662-665
A middle-aged male patient with recurrent hypoglycemia was diagnosed as insulinoma according to the symptoms and the laboratory tests. Laboratory tests also showed low cortisol and adrenocortico-tropic hormone (ACTH) levels, therefore adrenal insufficiency was diagnosed and hydrocortisone was given. The hormone replacement therapy was terminated after surgery, and ACTH and cortisol levels returned to normal.
Adrenal Insufficiency
;
drug therapy
;
etiology
;
Adrenocorticotropic Hormone
;
blood
;
Anti-Inflammatory Agents
;
therapeutic use
;
Humans
;
Hydrocortisone
;
therapeutic use
;
Insulinoma
;
complications
;
diagnosis
;
Male
;
Middle Aged
;
Treatment Outcome
4.The Effects of Aromatherapy on Stress and Stress Responses in Adolescents.
Journal of Korean Academy of Nursing 2009;39(3):357-365
PURPOSE: This study was done to examine the effects of aromatherapy on stress and stress responses in adolescents. METHODS: A two-group cross-over design was used for this study. The experimental treatment was aroma essential oil inhalation and the placebo treatment was carrier oil inhalation using a necklace. The sample included 36 female high school students. Fisher's exact test, t-test, and paired t-test using SPSS/WIN program were used to analyze the data. RESULTS: Stress levels were significantly lower when the students received the aroma treatment compared to when they received the placebo treatment. The stress responses except salivary IgA levels were significantly lower when the students received the aroma treatment. CONCLUSION: Aroma inhalation could be a very effective stress management method for high school students. Therefore, it is recommended that this program be used in clinical practice as an effective nursing intervention for high school students
Adolescent
;
Anxiety/psychology
;
*Aromatherapy
;
Blood Pressure
;
Demography
;
Female
;
Humans
;
Hydrocortisone/analysis
;
Immunoglobulin A/analysis
;
Plant Oils/*therapeutic use
;
Stress, Psychological/*therapy
5.Effect of somatostatin on postoperative gastrointestinal function and stress level in children with acute abdomen: a prospective randomized controlled study.
Bo-Xiang QI ; Lei ZHU ; Li-Ping SHENG ; Na-Na WEN ; Xiao CHENG ; Shuang-Shuang HU ; Tong QIAN
Chinese Journal of Contemporary Pediatrics 2022;24(7):812-816
OBJECTIVES:
To study the effect of somatostatin on postoperative gastrointestinal function and stress level in children with acute abdomen.
METHODS:
A total of 102 children with acute abdomen who underwent surgery in Xuzhou Children's Hospital from August 2019 to June 2021 were enrolled as subjects and were randomly divided into an observation group and a control group, with 51 children in each group. The children in the control group were given conventional treatment such as hemostasis and anti-infective therapy after surgery, and those in the observation group were given somatostatin in addition to conventional treatment. Peripheral blood samples were collected from both groups before surgery and on days 1 and 5 after surgery. The two groups were compared in terms of the serum levels of endothelin-1 (ET-1), adrenocorticotropic hormone (ACTH), cortisol, gastrin, and motilin, postoperative recovery, and the incidence rate of complications.
RESULTS:
There was no significant difference in the serum levels of ET-1, ACTH, cortisol, gastrin, and motilin between the two groups before surgery (P>0.05). Compared with the control group, the observation group had significantly lower serum levels of ET-1, ACTH, and cortisol on days 1 and 5 after surgery (P<0.05) and significantly higher levels of motilin and gastrin on day 5 after surgery (P<0.05). Compared with the control group, the observation group had significantly shorter time to first passage of flatus, first bowel sounds, and first defecation after surgery, as well as a significantly shorter length of hospital stay (P<0.05). The incidence rate of complications in the observation group was significantly lower than that in the control group (6% vs 24%, P<0.05).
CONCLUSIONS
In children with acute abdomen, somatostatin can significantly reduce postoperative stress response, improve gastrointestinal function, and reduce the incidence rate of complications, thereby helping to achieve a good prognosis.
Abdomen
;
Abdomen, Acute
;
Adrenocorticotropic Hormone
;
Child
;
Gastrins
;
Humans
;
Hydrocortisone
;
Motilin
;
Postoperative Complications
;
Prospective Studies
;
Somatostatin/therapeutic use*
6.Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases.
Yang Chun GU ; Ying LIU ; Chao XIE ; Bao Shan CAO
Journal of Peking University(Health Sciences) 2022;54(2):369-375
Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases SUMMARY Programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) have been widely used in lung cancer treatment, but their immune-related adverse events (irAEs) require intensive attention. Pituitary irAEs, including hypophysitis and hypopituitarism, are commonly induced by cytotoxic T lymphocyte antigen 4 inhibitors, but rarely by PD-1/PD-L1 inhibitors. Isolated adrenocorticotropic hormone(ACTH) deficiency (IAD) is a special subtype of pituitary irAEs, without any other pituitary hormone dysfunction, and with no enlargement of pituitary gland, either. Here, we described three patients with advanced lung cancer who developed IAD and other irAEs, after PD-1 inhibitor treatment. Case 1 was a 68-year-old male diagnosed with metastatic lung adenocarcinoma with high expression of PD-L1. He was treated with pembrolizumab monotherapy, and developed immune-related hepatitis, which was cured by high-dose methylprednisolone [0.5-1.0 mg/(kg·d)]. Eleven months later, the patient was diagnosed with primary gastric adenocarcinoma, and was treated with apatinib, in addition to pembrolizumab. After 17 doses of pembrolizumab, he developed severe nausea and asthenia, when methylprednisolone had been stopped for 10 months. His blood tests showed severe hyponatremia (121 mmol/L, reference 137-147 mmol/L, the same below), low levels of 8:00 a.m. cortisol (< 1 μg/dL, reference 5-25 μg/dL, the same below) and ACTH (2.2 ng/L, reference 7.2-63.3 ng/L, the same below), and normal thyroid function, sex hormone and prolactin. Meanwhile, both his lung cancer and gastric cancer remained under good control. Case 2 was a 66-year-old male with metastatic lung adenocarcinoma, who was treated with a new PD-1 inhibitor, HX008, combined with chemotherapy (clinical trial number: CTR20202387). After 5 months of treatment (7 doses in total), his cancer exhibited partial response, but his nausea and vomiting suddenly exacerbated, with mild dyspnea and weakness in his lower limbs. His blood tests showed mild hyponatremia (135 mmol/L), low levels of 8:00 a.m. cortisol (4.3 μg/dL) and ACTH (1.5 ng/L), and normal thyroid function. His thoracic computed tomography revealed moderate immune-related pneumonitis simultaneously. Case 3 was a 63-year-old male with locally advanced squamous cell carcinoma. He was treated with first-line sintilimab combined with chemotherapy, which resulted in partial response, with mild immune-related rash. His cancer progressed after 5 cycles of treatment, and sintilimab was discontinued. Six months later, he developed asymptomatic hypoadrenocorticism, with low level of cortisol (1.5 μg/dL) at 8:00 a.m. and unresponsive ACTH (8.0 ng/L). After being rechallenged with another PD-1 inhibitor, teslelizumab, combined with chemotherapy, he had pulmonary infection, persistent low-grade fever, moderate asthenia, and severe hyponatremia (116 mmol/L). Meanwhile, his blood levels of 8:00 a.m. cortisol and ACTH were 3.1 μg/dL and 7.2 ng/L, respectively, with normal thyroid function, sex hormone and prolactin. All of the three patients had no headache or visual disturbance. Their pituitary magnetic resonance image showed no pituitary enlargement or stalk thickening, and no dynamic changes. They were all on hormone replacement therapy (HRT) with prednisone (2.5-5.0 mg/d), and resumed the PD-1 inhibitor treatment when symptoms relieved. In particular, Case 2 started with high-dose prednisone [1 mg/(kg·d)] because of simultaneous immune-related pneumonitis, and then tapered it to the HRT dose. His cortisol and ACTH levels returned to and stayed normal. However, the other two patients' hypopituitarism did not recover. In summary, these cases demonstrated that the pituitary irAEs induced by PD-1 inhibitors could present as IAD, with a large time span of onset, non-specific clinical presentation, and different recovery patterns. Clinicians should monitor patients' pituitary hormone regularly, during and at least 6 months after PD-1 inhibitor treatment, especially in patients with good oncological response to the treatment.
Adenocarcinoma of Lung/drug therapy*
;
Adrenocorticotropic Hormone/therapeutic use*
;
Aged
;
B7-H1 Antigen/therapeutic use*
;
Humans
;
Hydrocortisone/therapeutic use*
;
Hyponatremia/drug therapy*
;
Hypopituitarism/drug therapy*
;
Immune Checkpoint Inhibitors
;
Lung Neoplasms/pathology*
;
Male
;
Methylprednisolone/therapeutic use*
;
Middle Aged
;
Nausea/drug therapy*
;
Pituitary Gland/pathology*
;
Pneumonia
;
Prednisone/therapeutic use*
;
Programmed Cell Death 1 Receptor/therapeutic use*
;
Prolactin/therapeutic use*
7.Successful Treatment of Primary Central Nervous System Lymphoma without Irradiation in Children: Single Center Experience.
Jong Hyung YOON ; Hyoung Jin KANG ; Hyery KIM ; Ji Won LEE ; June Dong PARK ; Kyung Duk PARK ; Hee Young SHIN ; Hyo Seop AHN
Journal of Korean Medical Science 2012;27(11):1378-1384
Primary CNS lymphoma (PCNSL) is a very uncommon disease in children, and usually treated by chemotherapy, combined with focal or craniospinal radiotherapy (RT). However, adverse effects of RT are a concern. We evaluated the outcomes of childhood PCNSL, treated with systemic and intrathecal chemotherapy, but without RT. For fifteen years, six patients among 175 of non-Hodgkin lymphoma were diagnosed as PCNSL in Seoul National University Children's Hospital and we analyzed their medical records retrospectively. Their male:female ratio was 5:1, and median age was 10.1 yr. The primary sites were the sellar area in three patients, parietal area in one, cerebellum in one, and multiple areas in one. Their pathologic diagnoses were diffuse large B-cell lymphoma in three patients, Burkitt lymphoma in two, and undifferentiated B-cell lymphoma in one. Five were treated with the LMB96 treatment protocol, and one was treated with the CCG-106B protocol. None had RT as a first-line treatment. One patient had a local relapse and received RT and salvage chemotherapy, without success. No patient had treatment-related mortality. Their estimated 5-yr event-free and overall survival rates were both 83.3%. In conclusion, PCNSL is a rare disease in childhood, but successfully treated by chemotherapy without RT.
Adolescent
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Central Nervous System Neoplasms/diagnosis/*drug therapy
;
Child
;
Child, Preschool
;
Cyclophosphamide/therapeutic use
;
Cytarabine/therapeutic use
;
Disease-Free Survival
;
Doxorubicin/therapeutic use
;
Etoposide/therapeutic use
;
Female
;
Humans
;
Hydrocortisone/therapeutic use
;
Infant
;
Leucovorin/therapeutic use
;
Lymphoma, Non-Hodgkin/diagnosis/*drug therapy
;
Male
;
Methotrexate/therapeutic use
;
Prednisone/therapeutic use
;
Recurrence
;
Retrospective Studies
;
Tomography, X-Ray Computed
;
Treatment Outcome
;
Vincristine/therapeutic use
8.Successful Treatment of Primary Central Nervous System Lymphoma without Irradiation in Children: Single Center Experience.
Jong Hyung YOON ; Hyoung Jin KANG ; Hyery KIM ; Ji Won LEE ; June Dong PARK ; Kyung Duk PARK ; Hee Young SHIN ; Hyo Seop AHN
Journal of Korean Medical Science 2012;27(11):1378-1384
Primary CNS lymphoma (PCNSL) is a very uncommon disease in children, and usually treated by chemotherapy, combined with focal or craniospinal radiotherapy (RT). However, adverse effects of RT are a concern. We evaluated the outcomes of childhood PCNSL, treated with systemic and intrathecal chemotherapy, but without RT. For fifteen years, six patients among 175 of non-Hodgkin lymphoma were diagnosed as PCNSL in Seoul National University Children's Hospital and we analyzed their medical records retrospectively. Their male:female ratio was 5:1, and median age was 10.1 yr. The primary sites were the sellar area in three patients, parietal area in one, cerebellum in one, and multiple areas in one. Their pathologic diagnoses were diffuse large B-cell lymphoma in three patients, Burkitt lymphoma in two, and undifferentiated B-cell lymphoma in one. Five were treated with the LMB96 treatment protocol, and one was treated with the CCG-106B protocol. None had RT as a first-line treatment. One patient had a local relapse and received RT and salvage chemotherapy, without success. No patient had treatment-related mortality. Their estimated 5-yr event-free and overall survival rates were both 83.3%. In conclusion, PCNSL is a rare disease in childhood, but successfully treated by chemotherapy without RT.
Adolescent
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Central Nervous System Neoplasms/diagnosis/*drug therapy
;
Child
;
Child, Preschool
;
Cyclophosphamide/therapeutic use
;
Cytarabine/therapeutic use
;
Disease-Free Survival
;
Doxorubicin/therapeutic use
;
Etoposide/therapeutic use
;
Female
;
Humans
;
Hydrocortisone/therapeutic use
;
Infant
;
Leucovorin/therapeutic use
;
Lymphoma, Non-Hodgkin/diagnosis/*drug therapy
;
Male
;
Methotrexate/therapeutic use
;
Prednisone/therapeutic use
;
Recurrence
;
Retrospective Studies
;
Tomography, X-Ray Computed
;
Treatment Outcome
;
Vincristine/therapeutic use
9.Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia.
Jia GUO ; Yi-Ping ZHU ; Ju GAO ; Qiang LI ; Cang-Song JIA ; Chen-Yan ZHOU ; Xia GUO
Journal of Experimental Hematology 2016;24(1):72-79
OBJECTIVETo explore the clinical and prognostic features as well as treatment response of childhood B-cell non-Hodgkin's lymphoma/acute lymphoblastic leukemia (B-NHL/B-ALL), so as to better modify the treatment for further improving the prognosis.
METHODSThe clinical data of 43 patients with newly-diagnosed childhood B-NHL/B-ALL from July 2005 to December 2013 in West China Second Hospital of Sichuan University were retrospectively analyzed with particular focus on clinical presentations, laboratory findings and histology. Among them 26 patients received B-NHL-2010 protocol and 17 patients received LMB-89 protocol treatment. Kaplan-Meier method was used to compare the survival rates between groups, while multiple factor logistic regression was used to identify the prognostic factors.
RESULTS(1) The median age at diagnosis was 7.58 (2.42-13.67) years. The male-to-female ratio was 2.9 : 1. No significant difference was found in the median age at diagnosis between male and female children with B-NHL/B-ALL (P = 0.837). (2) Burkitt's lymphoma was the most common (34/43, 79.07%), followed by diffuse large B cell lymphoma (4/43, 9.3%), ALL-L3 (3/43, 6.98%) and others (2/43, 4.65%) in decreasing frequency. (3) According to St. Jude staging classification, 4 patients (9.30%) were divided into stage I, 9 patients (20.93%) into stage II, 23 patients (53.49%) into stage III and 7 patients (16.28%) into stage IV; (4) Clinically, the common predilection sites were as following: ileocecus (11/43, 25.58%), nasopharynx (10/43, 23.26%), faciomaxillary (9/43, 20.93%), superficial lymphadenopathy (8/43, 18.60%), other sites such as mediastinum and bone marrow (5/43, 11.63%). (5) With a median follow up of 24 months (0.7-105 months), the 2-year overall survival (OS) rate and event-free survival (EFS) rate were 79.8% ± 6.5%% and 71.0% ± 7.2%, respectively. The 2-year OS and EFS rates in patients treated with B-NHL-2010 protocol were 79.1% ± 8.4% and 74.1% ± 8.4%, while those in patients treated with LMB-89 protocol were 87.5% ± 8.3% and 66.7% ± 12.4%, respectively, but there was no significant difference between them (P > 0.05). The 2-year EFS rate in patients with LDH > 2N and bone marrow infiltration were significantly lower than that of other groups (P < 0.05). (6) 8 patients (18.6%) relapsed. The median relapsed time was 6 months (2-9 months). 1 patient suffered progressive disease. Male, systemic symptom, elevated LDH, bone marrow and CNS infiltration and advanced stage (stage III and stage IV) were associated with relapse /progressive disease. Logistic regression analysis showed that LDH > 2N was an independent unfavorable prognostic factors (OR = 31.129, P = 0.02).
CONCLUSIONOutcome of B-NHL/B-ALL is greatly improved by current intensive and short-time chemotherapy regimen. The 2-year event-free survival (EFS) rate is 71.0% ± 7.2%. There is no significant difference in EFS rate between patients treated with B-NHL-2010 protocol and LMB89 protocol. The long-term survival rate in patient with advanced disease need to be further improved.
Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Burkitt Lymphoma ; diagnosis ; drug therapy ; Child ; Cyclophosphamide ; therapeutic use ; Cytarabine ; therapeutic use ; Disease-Free Survival ; Doxorubicin ; therapeutic use ; Etoposide ; therapeutic use ; Female ; Humans ; Hydrocortisone ; therapeutic use ; Leucovorin ; therapeutic use ; Logistic Models ; Lymphoma, B-Cell ; diagnosis ; drug therapy ; Lymphoma, Large B-Cell, Diffuse ; diagnosis ; drug therapy ; Male ; Methotrexate ; therapeutic use ; Multivariate Analysis ; Neoplasm Staging ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; diagnosis ; drug therapy ; Prednisone ; therapeutic use ; Prognosis ; Retrospective Studies ; Survival Rate ; Vincristine ; therapeutic use
10.A giant carotid aneurysm with intrasellar extension: a rare cause of panhypopituitarism.
Hannah SEOK ; Ha Neul PARK ; Gyo Hui KIM ; Hyun Shik SON ; Tae Seo SOHN
The Korean Journal of Internal Medicine 2015;30(2):265-266
No abstract available.
Aged
;
Anti-Inflammatory Agents/therapeutic use
;
Carotid Artery Diseases/*complications/diagnosis/therapy
;
Cerebral Angiography/methods
;
Diagnosis, Differential
;
Female
;
Glucocorticoids/therapeutic use
;
Humans
;
Hydrocortisone/therapeutic use
;
Hypopituitarism/diagnosis/*etiology/therapy
;
Intracranial Aneurysm/*complications/diagnosis/therapy
;
Magnetic Resonance Imaging
;
Plasma Substitutes/administration & dosage
;
Predictive Value of Tests
;
Prednisolone/therapeutic use
;
Sella Turcica
;
Thyroid Hormones/therapeutic use
;
Tomography, X-Ray Computed
;
Treatment Outcome